Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Overdose of Cu
2+
is associated with multiple diseases, such as
Wilson disease
,
Parkinson disease
, and Alzheimer disease. Therefore, detections of Cu
2+
in vivo and in vitro are meaningful. Near-infrared fluorescent probes are commonly applied for the detection of Cu
2+
in real time. With mono detection signal provided, these probes are not persuasive when applied to complicated biological environments, such as cells and animals. In this report, we conjugated the organic fluorescent probe CYDAC
16
with the UCNPs (lanthanide-doped upconversion nanoparticles) to develop a ratiometric luminescent probe for Cu
2+
. The composite material UCNPs-CYDAC
16
provides a ratiometric signal based on an upconversion luminescence 660 and 800 nm. With good sensitivity and selectivity for Cu
2+
, it works well in vivo and in vitro for the detection of Cu
2+
. We believe it is promising in further biological applications.
...
PMID:Dye-Assembled Upconversion Nanocomposite for Luminescence Ratiometric in Vivo Bioimaging of Copper Ions. 3048 7
Parkinson's disease
(PD) is a common neurodegenerative disorder. In 2015, The Movement Disorder Society Clinical Diagnostic Criteria for PD was published. In the criteria, the absolute exclusion criteria and red flags were designed to minimize diagnostic error, in particular to differentiate from neurodegenerative or secondary parkinsonism. Here, we reviewed neurodegenerative disorders that we should differentiate from PD. The common differential diagnoses, such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, and essential tremor are important but sometimes difficult to differentiate. We also described the features of rare but important differential diagnoses: neuronal intranuclear inclusion disease, Perry syndrome, Fragile X tremor/ataxia syndrome, Huntington's disease, dopa-responsive dystonia,
Wilson disease
, and neurodegeneration wit,1 brain iron accumulation.
...
PMID:Differential diagnosis of Parkinson's disease and other neurodegenerative disorders. 3056 95
This article reviews scales that have been developed for, validated in, and/or frequently used across multiple movement disorders with a focus on assessment of motor and nonmotor symptoms of
Parkinson disease
. Rating scales used in other disease states include those for essential tremor, dystonia (generalized dystonia, cervical dystonia, and blepharospasm), Tourette syndrome, Huntington disease, tardive dyskinesia,
Wilson disease
, ataxia, and functional movement disorders. Key features of each scale as well as cited criticisms and limitations of each scale are also discussed. Lastly, the article briefly discusses the emerging role of digital assessment tools (both wearable devices and digital interface applications).
...
PMID:Clinical Rating Scales and Quantitative Assessments of Movement Disorders. 3227 8
<< Previous
1
2
